FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic CancerThierry Conroy, Jean‐Baptiste Bachet, Petr Kavan et al.|New England Journal of Medicine|2018Cited by 2.8k
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic CancerThierry Conroy, Jean François Seitz, Florence Castan et al.|JAMA Oncology|2022Cited by 322
Inter‐ and intra‐tumoural heterogeneity in cancer‐associated fibroblasts of human pancreatic ductal adenocarcinomaCindy Neuzillet, Hemant M. Kocher, Annemilaï Tijeras‐Raballand et al.|The Journal of Pathology|2018Cited by 284
Clinical practice guidelines for BRCA1 and BRCA2 genetic testingPascal Pujol, Julie A. Vendrell, Massimo Barberis et al.|European Journal of Cancer|2021Cited by 174
Pacpaint: a histology-based deep learning model uncovers the extensive intratumor molecular heterogeneity of pancreatic adenocarcinomaCharlie Saillard, Jérôme Cros, F. Delecourt et al.|Nature Communications|2023Cited by 64